Leuprolide acetate (Fensolvi, Lupron Depot-PED, Lupron Depot)_Non-onc

Covers non‑oncology leuprolide acetate (Fensolvi, Lupron Depot‑PED, Lupron Depot) for central precocious puberty (Fensolvi and Lupron Depot‑PED), endometriosis, uterine fibroids, abnormal uterine bleeding (Lupron Depot only), preoperative hematologic improvement with concomitant iron (Lupron Depot), and compendial off‑label use for gender‑dysphoria; oncology indications are excluded. Coverage requires meeting age limits (Fensolvi ≥2 years; Lupron Depot‑PED pediatric), documentation of diagnosis and prior therapy or contraindications (Lupron Depot generally requires prior contraceptive/progestin/depo or alternative GnRH trial unless contraindicated), prescriber/consultant requirements for gender‑related use, adherence to specified dosing and approval durations (Fensolvi/Lupron Depot‑PED 12 months; Lupron Depot 3 months for fibroids, 6 months for AUB, 12 months for other indications), and concomitant iron for the preoperative anemia indication.

"Central precocious puberty (CPP) — Fensolvi"